Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 May;112(1):127–132. doi: 10.1111/j.1476-5381.1994.tb13041.x

Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum.

H Barelli 1, J E Fox-Threlkeld 1, V Dive 1, E E Daniel 1, J P Vincent 1, F Checler 1
PMCID: PMC1910296  PMID: 8032633

Abstract

1. The degradation of tritiated and unlabelled neurotensin (NT) following close intra-arterial infusion of the peptides in ileal segments of anaesthetized dogs was examined. 2. Intact NT and its catabolites recovered in the venous effluents were purified by chromatography on Sep-Pak columns followed by reverse-phase h.p.l.c. and identified by their retention times or by radioimmunoassay. 3. The half-life of neurotensin was estimated to be between 2 and 6 min. Four labelled catabolites, corresponding to free tyrosine, neurotensin (1-8), neurotensin (1-10) and neurotensin (1-11), were detected. 4. Neurotensin (1-11) was mainly generated by a phosphoramidon-sensitive cleavage, probably elicited by endopeptidase 24-11. 5. Two endopeptidase 3.4.24.16 inhibitors, phosphodiepryl 03 and the dipeptide Pro-Ile, dose-dependently potentiated the recovery of intact neurotensin. Furthermore, both agents inhibited the formation of neurotensin (1-10), the product that results from the hydrolysis of neurotensin by purified endopeptidase 3.4.24.16. In contrast, the endopeptidase 3.4.24.15 inhibitor Cpp-AAY-pAB neither protected neurotensin from degradation nor modified the production of neurotensin (1-10). 6. Our study is the first evidence to indicate that endopeptidase 3.4.24.16 contributes to the catabolism of neurotensin, in vivo, in the dog intestine.

Full text

PDF
129

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad S., Berezin I., Vincent J. P., Daniel E. E. Neurotensin receptors in canine intestinal smooth muscle: preparation of plasma membranes and characterization of (Tyr3-125I)-labelled neurotensin binding. Biochim Biophys Acta. 1987 Jan 26;896(2):224–238. doi: 10.1016/0005-2736(87)90183-0. [DOI] [PubMed] [Google Scholar]
  2. Ahmad S., Daniel E. E. Receptors for neurotensin in canine small intestine. Peptides. 1991 May-Jun;12(3):623–629. doi: 10.1016/0196-9781(91)90111-2. [DOI] [PubMed] [Google Scholar]
  3. Barelli H., Ahmad S., Kostka P., Fox J. A., Daniel E. E., Vincent J. P., Checler F. Neuropeptide-hydrolysing activities in synaptosomal fractions from dog ileum myenteric, deep muscular and submucous plexi. Their participation in neurotensin inactivation. Peptides. 1989 Sep-Oct;10(5):1055–1061. doi: 10.1016/0196-9781(89)90190-3. [DOI] [PubMed] [Google Scholar]
  4. Barelli H., Dive V., Yiotakis A., Vincent J. P., Checler F. Potent inhibition of endopeptidase 24.16 and endopeptidase 24.15 by the phosphonamide peptide N-(phenylethylphosphonyl)-Gly-L-Pro-L-aminohexanoic acid. Biochem J. 1992 Oct 15;287(Pt 2):621–625. doi: 10.1042/bj2870621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barelli H., Mao Y. K., Vincent B., Daniel E. E., Vincent J. P., Checler F. Differential catabolic fate of neuromedin N and neurotensin in the canine intestinal mucosa. Peptides. 1993 May-Jun;14(3):457–463. doi: 10.1016/0196-9781(93)90132-z. [DOI] [PubMed] [Google Scholar]
  6. Barelli H., Vincent J. P., Checler F. Peripheral inactivation of neurotensin. Isolation and characterization of a metallopeptidase from rat ileum. Eur J Biochem. 1988 Aug 15;175(3):481–489. doi: 10.1111/j.1432-1033.1988.tb14220.x. [DOI] [PubMed] [Google Scholar]
  7. Barelli H., Vincent J. P., Checler F. Rat kidney endopeptidase 24.16. Purification, physico-chemical characteristics and differential specificity towards opiates, tachykinins and neurotensin-related peptides. Eur J Biochem. 1993 Jan 15;211(1-2):79–90. doi: 10.1111/j.1432-1033.1993.tb19872.x. [DOI] [PubMed] [Google Scholar]
  8. Checler F., Ahmad S., Kostka P., Barelli H., Kitabgi P., Fox J. A., Kwan C. Y., Daniel E. E., Vincent J. P. Peptidases in dog-ileum circular and longitudinal smooth-muscle plasma membranes. Their relative contribution to the metabolism of neurotensin. Eur J Biochem. 1987 Jul 15;166(2):461–468. doi: 10.1111/j.1432-1033.1987.tb13538.x. [DOI] [PubMed] [Google Scholar]
  9. Checler F., Barelli H., Kitabgi P., Vincent J. P. Neurotensin metabolism in various tissues of central and peripheral origins: ubiquitous involvement of a novel neurotensin degrading metalloendopeptidase. Biochimie. 1988 Jan;70(1):75–82. doi: 10.1016/0300-9084(88)90161-7. [DOI] [PubMed] [Google Scholar]
  10. Checler F., Kostolanska B., Fox J. A. In vivo inactivation of neurotensin in dog ileum: major involvement of endopeptidase 24-11. J Pharmacol Exp Ther. 1988 Mar;244(3):1040–1044. [PubMed] [Google Scholar]
  11. Checler F., Vincent J. P., Kitabgi P. Purification and characterization of a novel neurotensin-degrading peptidase from rat brain synaptic membranes. J Biol Chem. 1986 Aug 25;261(24):11274–11281. [PubMed] [Google Scholar]
  12. Cuber J. C., Herrmann C., Kitabgi P., Bosshard A., Bernard C., De Nadai F., Chayvialle J. A. Neuromedin-N is not released with neurotensin from rat ileum. Endocrinology. 1990 Mar;126(3):1584–1592. doi: 10.1210/endo-126-3-1584. [DOI] [PubMed] [Google Scholar]
  13. Dauch P., Vincent J. P., Checler F. Specific inhibition of endopeptidase 24.16 by dipeptides. Eur J Biochem. 1991 Dec 5;202(2):269–276. doi: 10.1111/j.1432-1033.1991.tb16372.x. [DOI] [PubMed] [Google Scholar]
  14. Dive V., Yiotakis A., Nicolaou A., Toma F. Inhibition of Clostridium histolyticum collagenases by phosphonamide peptide inhibitors. Eur J Biochem. 1990 Aug 17;191(3):685–693. doi: 10.1111/j.1432-1033.1990.tb19175.x. [DOI] [PubMed] [Google Scholar]
  15. Goedert M., Hunter J. C., Ninkovic M. Evidence for neurotensin as a non-adrenergic, non-cholinergic neurotransmitter in guinea pig ileum. Nature. 1984 Sep 6;311(5981):59–62. doi: 10.1038/311059a0. [DOI] [PubMed] [Google Scholar]
  16. Hammer R. A., Carraway R. E., Leeman S. E. Elevation of plasma neurotensinlike immunoreactivity after a meal. Characterization of the elevated components. J Clin Invest. 1982 Jul;70(1):74–81. doi: 10.1172/JCI110605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kitabgi P. Effects of neurotensin on intestinal smooth muscle: application to the study of structure-activity relationships. Ann N Y Acad Sci. 1982;400:37–55. doi: 10.1111/j.1749-6632.1982.tb31559.x. [DOI] [PubMed] [Google Scholar]
  18. Kitabgi P., Freychet P. Neurotensin: contractile activity, specific binding, and lack of effect on cyclic nucleotides in intestinal smooth muscle. Eur J Pharmacol. 1979 Apr 1;55(1):35–42. doi: 10.1016/0014-2999(79)90145-6. [DOI] [PubMed] [Google Scholar]
  19. Manaka H., Manaka Y., Kostolanska F., Fox J. E., Daniel E. E. Release of VIP and substance P from isolated perfused canine ileum. Am J Physiol. 1989 Aug;257(2 Pt 1):G182–G190. doi: 10.1152/ajpgi.1989.257.2.G182. [DOI] [PubMed] [Google Scholar]
  20. Mashford M. L., Nilsson G., Rökaeus A., Rosell S. Release of neurotensin-like immunoreactivity (NTLI) from the gut in anaesthetized dogs. Acta Physiol Scand. 1978 Nov;104(3):375–376. doi: 10.1111/j.1748-1716.1978.tb06291.x. [DOI] [PubMed] [Google Scholar]
  21. Orci L., Baetens O., Rufener C., Brown M., Vale W., Guillemin R. Evidence for immunoreactive neurotensin in dog intestinal mucosa. Life Sci. 1976 Aug 15;19(4):559–561. doi: 10.1016/0024-3205(76)90236-8. [DOI] [PubMed] [Google Scholar]
  22. Roques B. P., Fournié-Zaluski M. C., Soroca E., Lecomte J. M., Malfroy B., Llorens C., Schwartz J. C. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature. 1980 Nov 20;288(5788):286–288. doi: 10.1038/288286a0. [DOI] [PubMed] [Google Scholar]
  23. Sadoul J. L., Mazella J., Amar S., Kitabgi P., Vincent J. P. Preparation of neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity and binding properties on mammalian neurotensin receptors. Biochem Biophys Res Commun. 1984 May 16;120(3):812–819. doi: 10.1016/s0006-291x(84)80179-5. [DOI] [PubMed] [Google Scholar]
  24. Sakai Y., Daniel E. E., Jury J., Fox J. E. Neurotensin inhibition of canine intestinal motility in vivo via alpha-adrenoceptors. Can J Physiol Pharmacol. 1984 Apr;62(4):403–411. doi: 10.1139/y84-064. [DOI] [PubMed] [Google Scholar]
  25. Suda H., Aoyagi T., Takeuchi T., Umezawa H. Letter: A thermolysin inhibitor produced by Actinomycetes: phospholamidon. J Antibiot (Tokyo) 1973 Oct;26(10):621–623. doi: 10.7164/antibiotics.26.621. [DOI] [PubMed] [Google Scholar]
  26. Umezawa H., Aoyagi T., Suda H., Hamada M., Takeuchi T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) 1976 Jan;29(1):97–99. doi: 10.7164/antibiotics.29.97. [DOI] [PubMed] [Google Scholar]
  27. de Nadai F., Cuber J. C., Kitabgi P. The characterization and regional distribution of neuromedin N-like immunoreactivity in rat brain using a highly sensitive and specific radioimmunoassay. Comparison with the distribution of neurotensin. Brain Res. 1989 Oct 23;500(1-2):193–198. doi: 10.1016/0006-8993(89)90313-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES